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Summary 
As antibiotic-resistant infections become increasingly prevalent worldwide, understanding 
the factors that lead to antimicrobial treatment failure is essential to optimizing the use of existing 
drugs. Opportunistic human pathogens in particular typically exhibit high levels of intrinsic 
antibiotic resistance and tolerance1, leading to chronic infections that can be nearly impossible to 
eradicate2. We asked whether the recalcitrance of these organisms to antibiotic treatment could be 
driven in part by their evolutionary history as environmental microbes, which frequently produce 
or encounter natural antibiotics3,4. Using the opportunistic pathogen Pseudomonas aeruginosa as 
a model, we demonstrate that the self-produced natural antibiotic pyocyanin (PYO) activates 
bacterial defenses that confer collateral tolerance to certain synthetic antibiotics, including in a 
clinically-relevant growth medium. Non-PYO-producing opportunistic pathogens isolated from 
lung infections similarly display increased antibiotic tolerance when they are co-cultured with 
PYO-producing P. aeruginosa. Furthermore, we show that beyond promoting bacterial survival in 
the presence of antibiotics, PYO can increase the apparent rate of mutation to antibiotic resistance 
by up to two orders of magnitude. Our work thus suggests that bacterial production of natural 
antibiotics in infections could play an important role in modulating not only the immediate efficacy 
of clinical antibiotics, but also the rate at which antibiotic resistance arises in multispecies bacterial 
communities.   
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Introduction 
The emergence and spread of bacterial resistance to clinical antibiotics is a growing public 
health concern worldwide2. Moreover, it is increasingly appreciated that antibiotic tolerance, 
defined as the ability to survive transient exposure to antibiotics, can also contribute to the failure 
of treatments for infections5. Yet bacterial resilience to antibiotics is anything but new: microbes 
in environments like soil have been producing natural antibiotics and evolving mechanisms of 
resistance and tolerance for millions of years1,3. We asked whether there could be a direct link 
between production of natural antibiotics by a human pathogen and recalcitrance of infections to 
clinical antibiotic treatment. One organism that fits this pattern is the opportunistic pathogen 
Pseudomonas aeruginosa, which is notorious for causing chronic lung infections in cystic fibrosis 
(CF) patients, as well as other types of infections in immunocompromised hosts6. P. aeruginosa 
produces several redox-active, heterocyclic compounds known as phenazines7. Despite possessing 
broad-spectrum antimicrobial activity7, including against P. aeruginosa itself8, phenazines have 
recently been shown to promote tolerance to clinical antibiotics under some circumstances, via 
mechanisms that have yet to be characterized9,10. Here, we sought to assess potential broader 
implications of the phenomenon by investigating whether phenazine-mediated tolerance to clinical 
antibiotics in P. aeruginosa is driven by cellular defenses that evolved to mitigate self-induced 
toxicity. In addition, we explored the ramifications of phenazine-induced tolerance for the 
evolution of bona fide antibiotic resistance, both in P. aeruginosa and in other clinically-relevant 
opportunistic pathogens.  
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Results 
Responses to the self-produced natural antibiotic pyocyanin and their effects on tolerance to 
clinical antibiotics 
We started by characterizing the defense mechanisms P. aeruginosa has evolved in 
response to its most toxic self-produced phenazine, pyocyanin (PYO)7,8. To do so in an unbiased 
fashion, we performed a genome-wide transposon sequencing (Tn-seq) screen in which the mutant 
library was exposed to PYO under starvation to maximize PYO toxicity8, and tolerance of the 
pooled mutants to PYO was assessed following re-growth (Fig. S1A). This revealed five broad 
categories of genes that significantly affect tolerance to PYO: (i) efflux systems, (ii) protein 
damage responses, (iii) membrane or cell wall biosynthesis, (iv) oxidative stress responses, and 
(v) carbon metabolism and transport (Fig. 1A). We validated the screen results by constructing 
and testing chromosomal clean deletion mutants for four of these genes (Fig. S1B). The strongest 
hits with a positive effect on PYO tolerance were transposon insertions in repressors of resistance-
nodulation-division (RND) efflux systems (Fig. 1A, Fig. S1B, Table S1), which would cause 
overexpression of the downstream efflux pumps. Transposon insertions in the genes encoding the 
efflux pump proteins themselves did not have strong effects in our screen (Table S1), likely due to 
functional redundancy among the various efflux systems11. Indeed, when we challenged starved 
P. aeruginosa with PYO in the presence of the broad-spectrum RND efflux inhibitor 
phenylalanine-arginine β-naphthylamide (PAβN), cell death was dramatically accelerated, 
confirming that efflux pumps are necessary for minimizing PYO toxicity (Fig. 1B).  
Mutations in the efflux system repressors identified in our Tn-seq screen are commonly 
found in clinical isolates that are resistant to fluoroquinolone antibiotics, as the efflux systems 
regulated by these repressors efficiently export this class of drugs12,13. Likewise, these repressors 
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were strong hits in a recent Tn-seq screen for genes that affect P. aeruginosa survival in the 
presence of the broad-spectrum fluoroquinolone ciprofloxacin14 (Fig. 1C, Fig. S1C, Table S1). We 
have also previously established that PYO upregulates expression of at least two efflux systems 
known to pump fluoroquinolones, mexEF-oprN and mexGHI-opmD8,15, in addition to the oxidative 
stress response genes ahpB (a thiol-specific peroxidase) and katB (a catalase)8; we confirmed the 
latter by performing qRT-PCR on the WT strain that produces PYO, a ∆phz mutant that does not 
produce PYO, and ∆phz treated with exogenous PYO (Fig. S2). Notably, phenazines and 
fluoroquinolones both contain at least one aromatic ring,  unlike other antibiotics that are not 
thought to be pumped by mexEF-oprN and mexGHI-opmD, such as aminoglycosides11 (Fig. 2A). 
Thus, structural similarities could account for why efflux pumps that likely evolved to export 
natural antibiotics such as PYO can also transport certain classes of synthetic antibiotics. To 
determine whether PYO also induces other efflux systems known to pump clinical antibiotics 
besides fluoroquinolones, we performed qRT-PCR on representative genes from all 11 major RND 
efflux systems in the P. aeruginosa genome. These measurements confirmed that mexEF-oprN 
and mexGHI-opmD are the only two efflux systems significantly induced by PYO, and that the 
induction is PYO dose-dependent (Figs. 2B, S3, and S4). The mexGHI-opmD system in particular 
reached expression levels comparable to the constitutively-expressed mexAB-oprM efflux system 
(Figs. 2B-left and S3), which plays an important role in the intrinsic antibiotic tolerance and 
resistance of P. aeruginosa11. 
Given that both efflux pumps and oxidative stress responses have previously been linked 
to antibiotic tolerance16,17, we asked whether the induction of these defenses by clinically-relevant 
concentrations of PYO18 could increase the tolerance of P. aeruginosa to clinical drugs. A survival 
assay (Fig. S5A) following treatment with clinical antibiotics revealed that, compared to the non-
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PYO-producing ∆phz mutant, the PYO-producing WT strain and PYO-treated ∆phz were more 
tolerant to both ciprofloxacin and another fluoroquinolone, levofloxacin (Fig. 2C). On the other 
hand, PYO did not confer increased tolerance to aminoglycosides (Fig. S5B), which are not 
substrates for the efflux pumps upregulated by PYO11. This finding contrasts with the conclusions 
of two previous studies on phenazine-mediated antibiotic tolerance, which claimed that phenazines 
broadly increase tolerance to all classes of antibiotics except cationic peptides9,10. However, one 
study focused on colony biofilms that produced only phenazine-1-carboxylic acid and phenazine-
1-carboxamide9, which are less toxic than PYO8 and consequently may induce a different set of 
cellular responses. Indeed, we found that aside from PYO, 1-hydroxyphenazine was the only other 
phenazine made by P. aeruginosa that increased tolerance to ciprofloxacin under our conditions, 
albeit to a lesser extent than PYO (Fig. S5C). The other previous study found that PYO increased 
planktonic culture cell densities in the presence of various antibiotics10, but these experiments did 
not directly demonstrate antibiotic tolerance5. Our results suggest that PYO preferentially induces 
tolerance to fluoroquinolones. Importantly, PYO also induced ciprofloxacin tolerance when P. 
aeruginosa was grown in synthetic cystic fibrosis sputum medium (SCFM) (Fig. 2C), suggesting 
that PYO production could contribute to antibiotic tolerance of this bacterium in CF patients. 
Under in vitro conditions, PYO is typically produced in early stationary phase15. However, 
the heterogeneous nature of physiological conditions in infections19,20 could lead to intermixing of 
PYO-producing and -non-producing cells in vivo. We therefore tested whether exogenous PYO 
could increase the fluoroquinolone tolerance of cells harvested during log phase, which did not 
make PYO. To limit the growth of the no-antibiotic control, we exposed these cells to the 
antibiotics under nitrogen depletion. PYO still increased tolerance to both ciprofloxacin and 
levofloxacin under these conditions, suggesting that the induced tolerance phenotype does not 
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depend on the metabolic state of stationary phase cells8 (Fig. S5B). Next, to visualize the recovery 
of cell growth after a transient exposure to ciprofloxacin, we performed a time-lapse microscopy 
assay (Fig. S5D). Interestingly, WT P. aeruginosa and PYO-treated ∆phz exhibited a shorter lag 
phase compared to non-PYO-treated ∆phz following ciprofloxacin treatment (Figs. 2D, E, S5E, 
and Movie S1), suggesting that PYO-induced defenses may help minimize cellular damage during 
the antibiotic treatment. We also found that addition of PYO to ∆phz increased ciprofloxacin 
tolerance in a dose-dependent manner (Fig. 2F), mirroring the dose-dependent induction of 
mexEF-oprN and mexGHI-opmD (Fig. 2A).  
Given that PYO-induced efflux pumps transport specific substrates11, we asked if increased 
drug efflux could be the primary mechanism underlying PYO-mediated tolerance to 
fluoroquinolones. At high concentrations of ciprofloxacin, addition of the efflux inhibitor PAβN 
eliminated the survival advantage of PYO-treated cells, indicating that efflux pump activity is 
necessary for the PYO-mediated increase in antibiotic tolerance (Fig. S5F). Next, we constructed 
a ∆phz strain with the mexGHI-opmD operon under the control of an arabinose-inducible promoter 
(Para:mexGHI-opmD). We verified that the transcription levels of mexGHI-opmD under arabinose 
induction were comparable to when PYO is present (Fig. S6). Indeed, arabinose induction of 
mexGHI-opmD expression increased ciprofloxacin tolerance to near-WT levels (Fig. 2G), 
suggesting that induction of this efflux system is sufficient to confer the PYO-mediated increase 
in tolerance. On the other hand, arabinose induction of the oxidative stress response genes ahpB 
or katB did not significantly increase tolerance of ∆phz to ciprofloxacin (Fig. S7). Importantly, the 
clinical relevance of mexGHI-opmD was previously not well known, as to our knowledge, there 
have been no reports of clinical mutants with constitutive overexpression of this efflux system. 
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Taken together, our results demonstrate that PYO-mediated regulation of mexGHI-opmD 
expression modulates tolerance to clinically-used antibiotics in P. aeruginosa. 
 
Pyocyanin promotes the evolution of antibiotic resistance 
 Previous studies have demonstrated that mutations conferring antibiotic tolerance or 
persistence promote the evolution of antibiotic resistance21,22. Moreover, tolerance mutations can 
1) interact synergistically with resistance mutations to increase bacterial survival during antibiotic 
treatment23 and 2) promote the establishment of resistance mutations during combination drug 
therapy24. Consequently, we performed fluctuation tests (Fig. 3A) to assess whether antibiotic 
tolerance induced by PYO could similarly promote the establishment of resistance mutations in 
populations of P. aeruginosa undergoing extended exposure to a clinical antibiotic. In clinical 
settings, antibiotic resistance is likely to result in treatment failure if a pathogen can grow at 
antibiotic concentrations above a threshold commonly referred to as a “breakpoint.” We adopted 
this criterion by selecting mutants on antibiotic concentrations either equal to or two-fold higher 
than the breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST)25. Furthermore, we added PYO to our cultures either prior to the antibiotic selection 
step and/or concurrently with the antibiotic selection, in order to distinguish between the effects 
of preemptive versus continuous induction of PYO-regulated cellular defenses. 
Historically, mutation rates inferred from fluctuation tests have sometimes been assumed 
to correlate with the per-base mutation rate across the genome26,27. However, the results from these 
assays can also be affected by the number of unique possible mutations that permit growth under 
the selection condition28. To encompass both possibilities in this study, we use the term µapp 
(apparent rate of mutation) as a proxy for the likelihood of evolving antibiotic resistance. We 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.04.20.049437doi: bioRxiv preprint 
calculated this parameter using standard methods for fluctuation test analysis (see Methods for 
details). Regardless of whether PYO was added prior to or concurrently with the antibiotic 
selection, PYO increased µapp for resistance to ciprofloxacin in both log-phase and stationary-
phase cultures (Fig. 3B, Fig. S8A). These results indicate that pre-treatment with PYO was 
sufficient but not necessary to increase µapp for fluoroquinolone resistance. Adding PYO at both 
stages of the fluctuation test resulted in an even greater increase in µapp (Fig. 3B), while the increase 
in µapp when PYO was added prior to antibiotic selection was dose-dependent (Fig. 3C). Similarly, 
cultures that were selected on levofloxacin also displayed an increased µapp upon PYO treatment 
(Fig. 3B). More importantly, PYO significantly increased µapp for cultures that were grown in 
liquid SCFM and selected on SCFM plates containing ciprofloxacin (Fig. 3D), suggesting that 
PYO produced by P. aeruginosa could promote mutation to antibiotic resistance in chronically 
infected lungs of CF patients29.  
Because tolerance to aminoglycosides was not affected by PYO (Fig. S5B), we 
hypothesized that defense mechanisms induced by PYO would not promote mutation to 
aminoglycoside resistance. On the other hand, if PYO affected µapp by acting as a mutagen, pre-
treatment with PYO before antibiotic selection would be expected to increase µapp for resistance 
to all classes of antibiotics. To differentiate between these modes of action, we repeated the 
fluctuation tests using gentamicin and tobramycin, representative members of the aminoglycoside 
family that disrupt protein translation2. Cultures that were pre-exposed to PYO exhibited increased 
µapp for gentamicin resistance, although adding PYO directly to the antibiotic plates had no effect 
(Fig. 3E). However, neither pre-treatment with PYO nor co-exposure to PYO in the antibiotic 
plates significantly increased µapp for tobramycin resistance (Fig. 3E). These differing responses 
to PYO depending on the choice of clinical antibiotic suggested that the observed changes in µapp 
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were related to the induction of cellular defenses rather than changes in the genome-wide per-base 
mutation rate. In fact, previous studies have suggested that gentamicin generates reactive oxygen 
species (ROS) more readily than tobramycin30,31. This could account for why pre-exposure to PYO 
increased µapp for resistance to gentamicin but not tobramycin, given that PYO primes cells to 
detoxify ROS by inducing oxidative stress responses (Fig. S2). For resistance to fluoroquinolones, 
on the other hand, it is likely that simultaneous induction of multiple defenses is necessary to 
recapitulate the increases in µapp upon exposure to PYO, as overexpression of individual genes 
induced by PYO did not significantly increase µapp (Fig. S8B, C). Interestingly, this contrasted 
with our finding that induction of the mexGHI-opmD efflux system was sufficient to recapitulate 
PYO-mediated increases in fluoroquinolone tolerance. Together, these results suggest that 
resistance is shaped by a different set of cellular processes compared to tolerance, but that PYO-
induced defense mechanisms nevertheless contribute to both types of resilience to antibiotic 
treatment. 
We envisioned three ways in which, under antibiotic selection, PYO-induced defense 
mechanisms could lead to the apparent increases in mutation rates: A) by enhancing the growth of 
pre-existing partially-resistant mutants; B) by increasing the proportion of cells that survive and 
subsequently mutate to resistance; or C) by a combination of A and B. To distinguish between 
these scenarios, we implemented a two-pronged approach. First, to explore the possibility of 
scenario A, we searched for and isolated partially-resistant mutants from the fluctuation test plates 
containing ciprofloxacin. We re-grew these isolates both with and without PYO treatment and 
calculated the percentage of CFUs recovered on ciprofloxacin plates relative to non-selective 
plates, as a metric for each isolate’s level of resistance. Second, to determine the relative 
likelihoods of scenario A and scenario B, we examined the fit of our fluctuation test data to 
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different formulations of the theoretical Luria-Delbrück (LD) distribution. Specifically, we 
compared mathematical models that make different assumptions regarding whether mutants arise 
prior to or during the antibiotic selection.  
We identified several partially-resistant mutants for which the percentage of CFUs 
recovered on ciprofloxacin plates increased when the isolate was either pre-exposed or co-exposed 
to PYO (Fig. 3F). Whole genome sequencing revealed that these isolates contained mutations 
either in the efflux pump repressors nfxB or mexS, or in genes that affected growth rate, such as a 
ribosomal protein and a C4-dicarboxylate transporter (Table S3). As a validation of our assay, we 
also tested isolates with distinct colony morphologies that were not enriched following exposure 
to PYO in the original fluctuation tests. As expected, these mutants were fully resistant to 
ciprofloxacin at the original selection concentration (Fig. S8D). Sequencing these isolates again 
revealed mutations in nfxB or mexS (Table S3), albeit at different loci. Interestingly, PYO did not 
affect the ciprofloxacin resistance of at least one partially-resistant isolate, CipR-40, a slow-growth 
mutant containing a 19-bp deletion in a cell wall synthesis gene (Fig. 3F, Table S3). This suggests 
that PYO does not universally raise the baseline MIC of the entire population, but rather interacts 
synergistically with specific types of mutations conferring partial resistance. We repeated the 
stationary phase ciprofloxacin tolerance assay with these partially-resistant isolates and found that 
tolerance was also differentially affected by PYO (Fig. S8E). The tolerance and resistance 
phenotypes shared no underlying pattern, again indicating that tolerance is influenced by different 
cellular processes compared to resistance. Nevertheless, our results demonstrate that under 
antibiotic selection, a subset of partially-resistant mutants benefit from exposure to PYO. 
That PYO increases µapp by promoting the growth of pre-existing partially-resistant 
mutants was further supported by the alternative approach of evaluating the fit of our data to 
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different mathematical models. Specifically, Pearson’s chi-square test indicated that our data 
closely fit the Hamon and Ycart model32 (Fig. S9, Table S2), which allows for differential fitness 
of mutants compared to WT cells, but assumes that all mutants arise pre-plating. However, we 
could not unequivocally rule out the possibility that post-plating mutations contributed to the 
increases in µapp, as a subset of our data also fit a mixed LD-Poisson model that assumes some 
mutations occurred during the antibiotic selection step33 (Fig. S9, Table S2). Together, these results 
suggest that the most probable explanation for PYO-mediated increases in apparent mutation rates 
is a combinatorial effect of increased detection of partially-resistant mutants and increased 
occurrence of post-plating mutations.  
Importantly, even two-fold increases in mutation rates have been shown to significantly 
promote the evolution of resistance to high antibiotic concentrations (>10x original MIC)34. 
Moreover, it is well-established that partial resistance can rapidly lead to acquisition of full 
resistance via secondary mutations35,36. Indeed, several putative mutants appeared fully resistant 
to ciprofloxacin despite being enriched by exposure to PYO in the fluctuation tests (Fig. S8F). 
This discrepancy could be a result of acquiring secondary mutations either during growth on the 
original fluctuation test plates or during the pre-growth for the CFU-recovery assay. Thus, our 
results suggest that PYO may significantly affect the rate at which high-level resistance emerges 
in populations of P. aeruginosa undergoing long-term antibiotic exposure. 
 
Impacts of pyocyanin on antibiotic tolerance and resistance in other opportunistic pathogens 
In both natural environments (e.g. soil) and clinical contexts (e.g. chronic infections), P. 
aeruginosa is found in multispecies microbial communities37–40. We hypothesized that microbes 
that frequently interact with P. aeruginosa would have evolved inducible defense mechanisms 
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against PYO toxicity, and that production of PYO by P. aeruginosa might therefore also increase 
tolerance and resistance to clinical antibiotics in these community members. To test this 
hypothesis, we focused on the genera Burkholderia and Stenotrophomonas, both of which are (i) 
soil-borne gram-negative opportunistic pathogens that are frequently refractory to clinical 
antibiotic treatments41–43, and (ii) found in co-infections with P. aeruginosa, e.g. in CF patients44. 
Specifically, we tested a soil-derived strain, Burkholderia cepacia ATCC 25416; a non-CF clinical 
isolate of Stenotrophomonas, S. maltophilia ATCC 13637; and several clinical isolates of the three 
most prevalent Burkholderia species found in CF patients37: B. cenocepacia, B. multivorans, and 
B. gladioli (for descriptions of these strains, see Table S4).  
We started by assessing each strain’s intrinsic resistance to PYO, as we expected that strong 
defenses against PYO toxicity would be required in order to benefit from exposure to this natural 
antibiotic. Indeed, for S. maltophilia, which was sensitive to PYO (Fig. S10A), the effects of PYO 
on antibiotic tolerance were complex: the presence of PYO was only beneficial when ciprofloxacin 
levels were low (1 µg/mL, which is below the MIC for this strain) (Fig. S10C). At a higher 
concentration of ciprofloxacin (10 µg/mL), PYO was detrimental in a dose-dependent manner 
(Fig. 4A), suggesting that the additional stress conferred by PYO outweighed any induction of 
defense mechanisms against ciprofloxacin. S. maltophilia also struggled to grow with P. 
aeruginosa in co-cultures (Fig. S10B, D), indicating that the conditions under which this species 
could potentially benefit from PYO are very limited. B. cepacia, B. cenocepacia, and B. 
multivorans, on the other hand, were highly resistant to PYO (Fig. S10A). For these three species, 
exogenously-added PYO increased tolerance to ciprofloxacin (Fig. 4B). Furthermore, for B. 
cepacia, we confirmed that this effect was PYO dose-dependent (Fig. 4B). We therefore tested 
whether P. aeruginosa could induce tolerance to ciprofloxacin in co-cultures with these 
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Burkholderia strains. Using liquid culture plates in which the two species were separated by a 
permeable membrane (Fig. S10B), we found that PYO-producing P. aeruginosa strongly induced 
tolerance to ciprofloxacin in the Burkholderia species, and that the observed tolerance phenotypes 
were recapitulated by addition of exogenous PYO to co-cultures of Burkholderia and the P. 
aeruginosa ∆phz mutant, or to control cultures with Burkholderia alone in the same setup (Fig. 
4C, Fig. S10E). Notably, for B. cenocepacia and B. multivorans, increased ciprofloxacin tolerance 
was also observed in co-cultures with a PYO-producing strain isolated from a CF patient, P. 
aeruginosa PA 76-11 (Fig. 4C, Fig. S10E). Moreover, similar results were obtained for co-cultures 
in SCFM (Fig. S10F). Together, these results suggest that PYO produced by P. aeruginosa in CF 
patients may decrease the efficacy of ciprofloxacin as a treatment for multispecies infections. 
We next asked whether PYO could mediate an increase in apparent mutation rate for 
ciprofloxacin resistance in Burkholderia species. We chose B. multivorans AU42096 (B. 
multivorans 1 in Fig. 4 and Fig. S10) as our model strain for these experiments because, among 
the clinical isolates, it displayed the strongest response to PYO in the ciprofloxacin tolerance 
assays. Remarkably, when selecting B. multivorans mutants on ciprofloxacin, we observed PYO-
mediated increases in µapp that were far more dramatic than for P. aeruginosa: pre-treatment with 
PYO increased µapp for B. multivorans approximately 10-fold, while co-exposure to PYO in the 
antibiotic plate without pre-exposure increased µapp approximately 40-fold, and the combination 
of pre- and co-exposure to PYO increased µapp by 230-fold (Fig. 4D, Table S2). Notably, the 
magnitude of the latter effect is on par with observed differences between hypermutators, such as 
mutants deficient in the mismatch repair pathway, and their respective parent strains45–47. 
Moreover, hypermutators of Burkholderia isolated from CF infections are associated with clinical 
ciprofloxacin resistance47. In light of these observations, our results suggest that PYO could 
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significantly affect clinical outcomes for co-infections of P. aeruginosa and B. multivorans treated 
with ciprofloxacin. 
To verify that the B. multivorans colonies growing on ciprofloxacin in the presence of PYO 
were mutants, and to assess their responses to PYO, we isolated several putative mutants from the 
fluctuation test antibiotic plates and tested three in our CFU-recovery assay. All three displayed 
unique profiles of ciprofloxacin resistance in response to PYO treatment, as well as different 
maximal levels of resistance, though none were noticeably resistant to ciprofloxacin without 
exposure to PYO (Fig. 4E). Whole-genome sequencing of these isolates revealed that B. 
multivorans CipR-1 possessed mutations in three uncharacterized regulatory genes (Table S5). B. 
multivorans CipR-2 possessed mutations in two different homologs of the SpoT/RelA (p)ppGpp 
synthetase gene, which is known to affect antibiotic tolerance and resistance48. B. multivorans 
CipR-7 possessed a point mutation in DNA gyrase A (S83R), along with a point mutation in a 
malto-oligosyltrehalose synthase. Given that DNA gyrase A is the target of ciprofloxacin and that 
the specific mutated residue is likely homologous to the T83 residue that was mutated in a study 
of fluoroquinolone-resistant mutants in B. cepacia49, it is intriguing that this mutant was not fully 
resistant to ciprofloxacin in the absence of PYO; however, the specific amino acid substitution in 
this strain may have resulted in only a mild disruption of ciprofloxacin binding.  
Lastly, we asked whether the B. multivorans mutants we detected primarily arose prior to 
or during the antibiotic selection. In all cases, the distribution of mutants closely matched the 
Hamon and Ycart formulation of the theoretical LD distribution, suggesting that the detected 
mutants arose prior to the antibiotic exposure (Fig. S11, Table S2). Interestingly, the Hamon and 
Ycart model also predicted the average relative fitness of mutants detected in PYO-treated samples 
to be significantly lower compared to mutants detected in non-PYO treated samples (Table S2; p 
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< 0.05 for all three comparisons between non-PYO-treated and PYO-treated sample groups, using 
Welch’s paired t-test with Benjamini-Hochberg corrections for controlling the false discovery 
rate). In addition, unlike for P. aeruginosa, the mixed LD-Poisson distribution that allows for post-
plating mutations was a poorer fit than the Hamon and Ycart model for all PYO-treated B. 
multivorans samples (Fig. S11, Table S2). Together, these results suggest that in B. multivorans, 
PYO increases µapp by promoting growth of a wider range of mutants that arise prior to antibiotic 
selection, including those with slower growth rates.   
 
Discussion 
  Chronic infections are frequently caused by opportunistic pathogens whose long 
evolutionary history in the presence of natural antibiotics has potentially primed them for resilience 
against clinical antibiotic treatments. Indeed, many clinical antibiotic resistance genes are thought 
to have originated in environmental microorganisms as responses to microbial chemical warfare, 
with subsequent mobilization into human pathogens via horizontal gene transfer1,3,4. Here, we have 
demonstrated that tolerance and resistance to clinically-relevant concentrations of synthetic 
antibiotics can also arise as a collateral benefit of natural antibiotic production by an opportunistic 
pathogen.  
P. aeruginosa is a particularly relevant example of an opportunistic pathogen whose self-
produced natural antibiotics can promote tolerance and resistance to clinical antibiotics, given the 
large number of chronic infections caused by this bacterium worldwide6 and the fact that PYO has 
been detected in lung infection sputum samples at concentrations up to 130 µM18. Notably, 
treatments for infections caused by P. aeruginosa and other opportunistic pathogens often fail even 
when in vitro MIC tests indicate susceptibility to the chosen antibiotic44. Previous studies have 
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attributed this discrepancy to metabolic and physiological changes within biofilms50,51, which 
represent a major form of bacterial life within infections52. Our results suggest that cellular 
defenses induced by bacterially-produced natural antibiotics may also contribute to in vitro versus 
in vivo differences in antibiotic susceptibility, as standard MIC tests are inoculated at a low cell 
density25, but P. aeruginosa typically does not make PYO in vitro until reaching a relatively high 
cell density15. Furthermore, the observation that PYO produced by P. aeruginosa strongly 
promotes antibiotic tolerance and resistance in Burkholderia species could hold important 
ramifications for the treatment of co-infections of these organisms in CF patients, for which clear 
best practices have yet to be established44. In particular, it could be prudent to avoid treating such 
infections with antibiotics for which PYO is likely to promote increased tolerance and resistance, 
such as fluoroquinolones, chloramphenicol, and trimethoprim/sulfamethoxazole—the latter two 
also being known substrates for efflux pumps that we have shown are upregulated by PYO6,11.  
  Finally, we note that our proposed model for collateral benefits of exposure to natural 
antibiotics (Fig. S12) potentially represents a broader phenomenon among human pathogens than 
has previously been appreciated. Many opportunistic pathogens originate in environments like 
soil41,53, where they have evolved in the presence of diverse natural antibiotics1,3, and P. 
aeruginosa is not the only pathogen with the capacity to synthesize its own antibiotics. For 
example, Burkholderia species possess the biosynthetic capability to produce a variety of 
compounds with antibacterial activity, whose potential clinical significance has not been 
explored54. If a given natural antibiotic induces efflux systems as a defense response, the only 
requirement for a consequent increase in tolerance to a clinically-relevant drug would be that the 
induced efflux system has some efficacy in transporting that drug—e.g. due to structural 
similarities like those shared by PYO and fluoroquinolones. This inference is supported by recent 
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evidence that certain food additives or synthetic drugs antagonize the efficacy of specific clinical 
antibiotics by triggering stress responses in cells, including the induction of efflux pumps55. In 
fact, bacterially-produced toxic metabolites that promote antibiotic tolerance and resistance in 
human pathogens need not be limited to the types of molecules traditionally thought of as natural 
antibiotics. For example, indole secretion by highly antibiotic-resistant spontaneous mutants of E. 
coli enables partially-resistant mutants within the same species to grow at drug concentrations 
above their own MICs, in part by stimulating efflux pump expression56. Unlike PYO, indole is 
generally thought of as a signaling molecule rather than a natural antibiotic57, though it can 
likewise be toxic to bacteria at high concentrations57,58. Efforts to identify and characterize 
additional examples of such metabolites produced by opportunistic human pathogens could lead 
to an improved understanding of the modes of antibiotic treatment failure in clinics, and ultimately 
inform the design of more effective and longer-lived therapies.  
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Fig. 1. Mechanisms of tolerance to the self-produced natural antibiotic PYO in P. aeruginosa. 
A. Statistically significant fitness effects of transposon insertions in different representative genes 
under conditions that maximize PYO toxicity, as revealed by a genome-wide transposon 
sequencing (Tn-seq) screen (for experimental design, see Fig. S1A; for full dataset, see Table S1). 
See Methods for details on calculation of fitness. Asterisks show genes for which chromosomal 
clean deletion mutants were constructed and validated (Fig. S1B). B. Tolerance to PYO toxicity 
in the presence and absence of the efflux inhibitor PAβN. Each data point represents an 
independent biological replicate (n = 4), and the horizontal black lines mark the mean survival for 
each condition and time point. C. Fitness correlation analysis between PYO tolerance Tn-seq (this 
study) and CP persistence Tn-seq13. Efflux repressors present in both datasets are highlighted in 
green; mexS was not present in the CP Tn-seq dataset, while nalC is not shown in panel A because 
it was not statistically significant in our PYO Tn-seq despite its large effect on fitness, likely due 
to an insufficient number of unique transposon insertions in that gene. For full analysis, see Fig. 
S1C and Table S1. 
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Fig. 2. PYO induces expression of specific efflux systems, conferring cross-tolerance to 
fluoroquinolones. A. Structures of PYO, two representative fluoroquinolones (CP = 
ciprofloxacin, LV = levofloxacin) and two representative aminoglycosides (GM = gentamicin, TM 
= tobramycin). PYO and fluoroquinolones are pumped by MexEF-OprN and MexGHI-OpmD, 
while aminoglycosides are not11. Rings with an aromatic character are highlighted in red. B. 
Normalized cDNA levels for genes within operons coding for the 11 main RND efflux systems in 
P. aeruginosa (left). PYO-dose-dependent changes in expression of mexEF-oprN and mexGHI-
opmD systems (right; n = 3). For full qRT-PCR dataset, see Figs. S2, S3 and S4. C. Effect of PYO 
on tolerance to CP and LV in glucose minimal medium (left), and to CP in SCFM (right) (all 1 
µg/mL) (n = 4). PYO itself was not toxic under the experimental conditions8. WT made 50-80 µM 
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PYO as measured by absorbance of the culture supernatant at 691 nm. See Fig. S5A for 
experimental design. D-E. Effect of PYO on lag during outgrowth after exposure to CP. A 
representative field of view over different time points (D; magenta = WT::mApple, green = 
∆phz::GFP; see Movie S1) is shown together with the quantification of growth area on the agarose 
pads at time 0 hrs and 15 hrs (E). For these experiments, a culture of each strain tested was grown 
and exposed to CP (10 µg/mL) separately, then cells of both cultures were washed, mixed and 
placed together on a pad and imaged during outgrowth. The pads did not contain any PYO or CP 
(see Methods and Fig. S5D for details). White arrows in the displayed images point to regions with 
faster recovery of WT growth. The field of view displayed is marked with a black arrow in the 
quantification plot. The results for the experiment with swapped fluorescent proteins are shown in 
Fig. S5E. Scale bar: 20 µm. F. Tolerance of ∆phz to CP (1 µg/mL) in stationary phase in the 
presence of different concentrations of PYO (n = 4). G. Tolerance of ∆phz to CP (1 µg/mL) upon 
artificial induction of the mexGHI-opmD operon with arabinose (n = 4). The dashed green line 
marks the average survival of PYO-producing WT under similar conditions (without arabinose). 
Statistics: C, F – One-way ANOVA with Tukey’s HSD multiple-comparison test, with asterisks 
showing significant differences relative to untreated ∆phz (no PYO); E, G – Welch’s unpaired t-
test (* p < 0.05, ** p < 0.01, *** p < 0.001, n.s. p > 0.05). In all panels with quantitative data, 
black horizontal lines mark the mean value for each condition. Individual data points represent 
independent biological replicates, except for in panel E, where the data points represent different 
fields of view.  
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Fig. 3. PYO increases the apparent rate of mutation to antibiotic resistance. A. Experimental 
design for fluctuation tests to determine the effect of PYO (100 µM unless otherwise noted) on 
apparent mutation rates. For panels B-E, mutation rates were calculated using an established 
maximum likelihood-based method that accounts for the effects of plating a small proportion of 
the total culture volume (see Methods for details). Each data point in those panels represents a 
single biological replicate comprising 44 parallel cultures. B. Apparent mutation rates of log-phase 
∆phz grown in glucose minimal medium and plated on MH agar containing ciprofloxacin (CP, 0.5 
µg/mL; n = 4) or levofloxacin (LV, 1 µg/mL; n = 5), with or without pre- and/or co-exposure to 
PYO relative to the antibiotic selection step. C. The apparent rate of mutation to resistance for 
∆phz cells that were pre-treated with different concentrations of PYO and plated onto CP (0.5 
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µg/mL). Lines connect data points from the same biological replicate. D. Apparent mutation rates 
of log-phase ∆phz grown PYO in SCFM and plated on SCFM agar containing CP (1 µg/mL; n = 
4) with or without pre- and/or co-exposure to PYO. E. Apparent mutation rates of log-phase ∆phz 
grown -/+ PYO in glucose minimal medium and plated during onto MH agar containing 
gentamicin (GM, 16 µg/mL; n = 4) or tobramycin (TM, 4 µg/mL; n = 4), with or without pre- 
and/or co-exposure to PYO. F. The percentage of CFUs recovered on CP (0.5 µg/mL) with or 
without PYO in the agar, for log-phase cultures of different partially-resistant mutants or ∆phz that 
were pre-grown with or without PYO in glucose minimal medium. Percentage recovery was 
calculated relative to total CFUs counted on non-selective plates. Data points represent 
independent biological cultures (n = 4). Statistics: B, D, E – Welch’s paired t-tests with Benjamini-
Hochberg correction for controlling false discovery rate; F – Welch’s unpaired t-tests with 
Benjamini-Hochberg correction for controlling false discovery rate (* p < 0.05, ** p < 0.01, *** 
p < 0.001, n.s. p > 0.05). In B, C, E, and F, black horizontal lines mark the mean values for each 
condition. 
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Fig. 4. PYO promotes antibiotic tolerance and resistance in other opportunistic pathogens. 
A. Dose-dependent effect of PYO on S. maltophilia tolerance to high levels of ciprofloxacin (10 
µg/mL; n = 4). B. Effect of PYO on the tolerance to ciprofloxacin (10 µg/mL) of multiple 
Burkholderia species isolated from environmental and clinical samples (n = 4). C. Effect of PYO 
produced by P. aeruginosa in co-cultures on the tolerance of different Burkholderia species to 
ciprofloxacin (10 µg/mL). PA14 is our model laboratory strain of P. aeruginosa, while PA 76-11 
is a PYO-producing strain of P. aeruginosa isolated from a CF patient. The Burkholderia strains 
were plated separately for CFUs to assess survival following treatment with ciprofloxacin in the 
co-cultures (n = 3). See Fig. S10B for experimental design. D. The apparent rate of mutation to 
resistance when log-phase B. multivorans 1 cells were plated on MH agar containing ciprofloxacin 
(8 µg/mL), with or without pre- and/or co-exposure to 100 µM PYO relative to the antibiotic 
selection step. Each data point represents a biological replicate comprising 44 parallel cultures (n 
= 4). E. The percentage of CFUs recovered on ciprofloxacin plates either with or without PYO in 
the agar, for exponential phase cultures of different partially-resistant B. multivorans 1 mutants 
that were pre-grown with or without PYO in liquid cultures. Percentage recovery was calculated 
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relative to total CFUs counted on non-selective plates (n = 4). Statistics: A, B, C – One-way 
ANOVA with Tukey’s HSD multiple-comparison test for comparisons of three conditions or 
Welch’s unpaired t-test for comparison of two conditions, with asterisks showing the statistical 
significance of comparisons with the untreated (no PYO) condition; D, E – Welch’s paired (D) or 
unpaired (E) t-tests with Benjamini-Hochberg correction for controlling false discovery rate (* p 
< 0.05, ** p  < 0.01, *** p < 0.001). In all panels, data points represent independent biological 
replicates, and black horizontal bars mark the mean values for each condition. 
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Methods 
Culture media and incubation conditions 
 Different culture media were used for different experiments as indicated throughout the 
Methods. Succinate minimal medium (SMM) composition was: 40 mM sodium succinate (or 20 
mM, if specified), 50 mM KH2PO4/K2HPO4 (pH 7), 42.8 mM NaCl, 1 mM MgSO4, 9.35 mM 
NH4Cl, and a trace elements solution59. Glucose minimal medium (GMM) was identical to 
SMM, except with 10 or 20 mM glucose (as specified for different experiments) instead of 
succinate. SMM and GMM were prepared by autoclaving all components together for 20 min at 
121°C, except for the carbon source and the 1000x trace elements stock solution, which were 
filter-sterilized and added separately; interestingly, we found that autoclaving MgSO4 with the 
other components was crucial for consistent PYO production by WT Pseudomonas aeruginosa 
UCBPP-PA14 in GMM. Luria-Bertani (LB) Miller broth (BD Biosciences) and BBLTM Cation-
Adjusted Mueller-Hinton II (MH) broth (BD Biosciences) were prepared according to the 
manufacturer’s instructions (notably with only a 10 min autoclave step for MH medium), with 
the addition of 1.5% BactoTM agar (BD Biosciences) to make solid media. Synthetic cystic 
fibrosis sputum medium (SCFM) composition was as described in previously29, with the addition 
of 3.6 µM FeSO4 and 0.3 mM N-acetyl-glucosamine60. All components except for the latter two 
were dissolved together, sterilized by filtration through a 0.22 µm membrane, and stored for up 
to two weeks; FeSO4 and N-acetyl-glucosamine solutions were prepared fresh each time or 
stored at -20 ºC, respectively, and added to SCFM on the day of use. For SCFM agar, a 2x 
solution of the medium components was prepared and added to a separately autoclaved 3% 
molten agar solution, for a final concentration of 1x SCFM and 1.5% agar.  
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Antibiotics were prepared in concentrated stock solutions (100x or greater) and stored at -
20ºC. Ciprofloxacin was dissolved in 0.1 M or 20 mM HCl, while levofloxacin, gentamicin, and 
tobramycin were dissolved in sterile deionized water. Phenylalanine-arginine β-naphthylamide 
(PAbN) dihydrochloride (MedChemExpress) was dissolved in sterile deionized water (50 
mg/mL). Pyocyanin (PYO) was synthesized and purified as previously described61,62 and 
dissolved in 20 mM HCl to make 10 mM stock solutions. Experiments involving exogenous 
PYO always included negative controls to which an equivalent volume of 20 mM HCl was 
added. In addition, MH agar plates were buffered to pH 7 with 10 mM 
morpholinepropanesulfonic acid (MOPS) to avoid any pH changes upon addition of PYO or 
HCl; all other media used with exogenous PYO were already inherently buffered. Incubations 
were always done at 37ºC, with shaking for liquid cultures (250 rpm), unless mentioned 
otherwise.  
 
Strain construction 
 In this study, we use PA14 as an abbreviation for UCBPP-PA14. P. aeruginosa PA14 
was used for all experiments unless otherwise noted. For a full list of strains made in this study, 
see Table S4. Three types of strains were made in different P. aeruginosa PA14 backgrounds: (i) 
unmarked deletions, used for Tn-seq validation experiments; (ii) fluorescent strains for time-
lapse microscopy experiments; and (iii) strains overexpressing one of the following three 
systems: mexGHI-opmD, ahpB and katB. Established protocols were used for all these 
procedures63.  
Briefly, for unmarked deletions, ~1kb fragments immediately upstream and downstream 
of the target locus were cloned using Gibson assembly into the pMQ30 suicide vector 64,65. 
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Fragments amplified from P. aeruginosa PA14 genomic DNA (gDNA) and cleaned up using the 
Monarch PCR Purification kit (New England Biolabs) were used for Gibson assembly together 
with pMQ30 cut with SacI and HindIII. The assembled construct was then transformed into 
Escherichia coli DH10B, with transformants being selected in LB with 20 µg/mL gentamicin. 
All correctly-assembled plasmids were identified by colony PCR and verified by Sanger 
sequencing (Laragen). Next, for the insertion of the constructs into P. aeruginosa PA14 genome, 
tri-parental conjugation was performed following Choi and Schweizer66. All unmarked deletions 
were done in the P. aeruginosa PA14 ∆phz background (both phzA-G1 and phzA-G2 operons are 
deleted in this strain15), allowing clean experiments by addition of exogenous phenazines. 
Merodiploids containing the construct integrated into their genomes were selected on VBMM 
medium (3 g/L trisodium citrate, 2 g/L citric acid, 10 g/L K2HPO4, 3.5 g/L NaNH4PO4·4H2O, 1 
mM MgSO4, 100 µM CaCL2, pH 7) with 100 µg/mL gentamicin following Choi and 
Schweizer66. Finally, merodiploids were then plated on LB lacking NaCl and containing 10% 
sucrose to select for colonies resulting from homologous recombination. Colonies missing the 
target locus (unmarked deletions) were identified by PCR. For all primers used, see Table S4.  
Fluorescent strains used in time-lapse microscopy were made using previously published 
plasmids63,67. Constructs containing GFP and mApple florescent proteins under the control of the 
ribosomal rpsG gene were inserted in the attTn7 site of P. aeruginosa PA14 ∆phz chromosome 
by tetra-parental conjugation, followed with selection on VBMM with 100 µg/mL gentamicin66.   
 Finally, overexpressing strains were made as previously described63. The previously 
made overexpression construct (pUC18T-miniTn7T-GmR vector containing the arabinose-
inducible promoter Para63) and the three different targets (mexGHI-opmD, ahpB and katB) were 
all amplified by PCR. Next, using Gibson assembly, the targets were cloned downstream of Para 
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in the pUC18T-miniTn7T-GmR vector, resulting in the three different overexpression constructs: 
Para:mexGHI-opmD, Para:ahpB, and  Para:katB. The final constructs were introduced into the 
attTn7 of the P. aeruginosa PA14 ∆phz background strain by tetraparental conjugation66. 
 
Transposon-sequencing (Tn-seq) experiment  
 The Tn-seq experiment was performed following the design presented in Fig. S1A. Two 
aliquots of the P. aeruginosa PA14 transposon library previously prepared67 were thawed on ice 
for 15 min, diluted to a starting optical density (OD500) of 0.05 in 50 mL of SMM, and grown 
aerobically under shaking conditions (250 rpm) at 37 ºC for ~ 4-5 generations to an OD500  of 
0.8-1. These growing conditions were used for all the stages of the experiment. After growth in 
SMM, each aliquot was considered an independent replicate. Cells from each replicate were 
pelleted, washed and resuspended (5 mL in 18 x 150 mm glass tubes, OD500 = 2) in minimal 
phosphate buffer (MPB - 50 mM KH2PO4/ K2HPO4[pH 7], 42.8 mM NaCl) with and without 
100 µM PYO. Cells were then incubated for 26 hrs under shaking conditions at 37º C. Therefore, 
the experiment consisted of four different samples that were later sequenced: (i) “R1 No PYO”, 
(ii) “R1 + PYO”, (iii) “R2 No PYO” and (iv) “R2 + PYO”. After the incubation, cultures from 
all treatments were pelleted, washed again to remove PYO, and resuspended in fresh SMM. 
Immediately, an aliquot of each sample was diluted to a starting OD500 of ~ 0.05 in 25 mL SMM, 
followed by outgrowth for ~ 4-5 generations to an OD500 of 0.8-1. After outgrowth, 2.5 mL of 
each sample was pelleted and stored at -80 ºC.  
 Genomic DNA was extracted from the pelleted samples using the DNeasy Blood & 
Tissue kit (Qiagen). All the steps for sequencing library preparation followed exactly the 
protocol used by Basta et al.67, including (i) DNA shearing by sonication (to produce 200-500 bp 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.04.20.049437doi: bioRxiv preprint 
fragments), (ii) end-repair, (iii) addition of poly(C) tail and (iv) enrichment of transposon-
genome junctions and addition of adapter for Illumina sequencing by PCR67,68. The resulting 
amplified DNA samples were sequenced using 100 bp single-end reads on the Illumina HiSeq 
2500 platform at the Millard and Muriel Jacobs Genetics and Genomics Laboratory at Caltech. 
Data analysis also followed Basta et al.67. In summary, sequences were mapped to the P. 
aeruginosa UCBPP-PA14 genome sequence using Bowtie 269 and were analyzed in MATLAB 
using the ARTIST Tn-Seq analysis pipeline70, with non-overlapping windows of 100 bp across 
the genome67,70. Using Mann-Whitney U statistical test, the total reads mapping for each gene in 
the “+PYO” samples were compared to the corresponding reads in the “No PYO” control for 
each replicate independently67,70. Next, the read ratio for each replicate was calculated within 
ARTIST for each gene and then log2-transformed. Finally, the p-values for both replicates were 
combined using the Fisher’s combined probability test as done in Basta et al.67, and the average 
of the log2-ratios of the two replicates are also shown. For the log2-ratios and p-values for all 
PA14 genes, see Table S1. For heatmaps shown in Fig. 1A, the average log2-ratios (fitness) for 
the selected genes were plotted using the geom_tile() function from the ggplot2 package in R71,72. 
 
Tn-seq datasets correlation analysis 
 To compare the results of this Tn-seq analysis with a previously published study14 
analyzing fitness determinants for survival during ciprofloxacin treatment in the P. aeruginosa 
PAO1 strain background (Fig. 1C, S1C and Table S1), the data from that study’s supplemental 
Table S1 were used. The normalized average ratio of reads in the treated sample compared to 
reads in the input sample for each gene (geometric mean of 3 replicates) was log2-transformed 
for comparison to the Tn-seq data described above. The list of genes was filtered to include only 
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genes for which ratios were reported in both our PYO Tn-seq experiment and the ciprofloxacin 
Tn-seq study, and for which there are clear orthologs in both strains (n = 4209 genes). Orthologs 
were determined using the “pseudomonas.com” database73. 
 
Tn-seq validation experiments 
 To validate the Tn-seq results (Fig. S1B), experiments were performed by comparing 
survival of four different mutants (∆phz∆ackA∆pta, ∆phz∆lptA, ∆phz∆mexS and ∆phz∆dctBD) to 
the survival of the ∆phz strain upon exposure to PYO. The experimental design was very similar 
to the one used in for the Tn-seq, with minor adaptations. An overnight culture (5 mL) of each 
strain was grown in SMM (40 mM succinate) from LB plates. Cells were washed and re-
suspended at an OD500 of 0.1 (or 0.25 for ∆phz∆dctBD) in the same medium to start the new 
cultures (5 mL), which were grown to OD500 ~ 0.8-1, pelleted, washed, and re-suspended in the 
same minimal medium without succinate (no carbon source) at OD500 of 1. For each strain, the 
culture was split across 8-12 wells (150 µL cultures) in a 96-well plate, with 100 µM PYO added 
to half of the cultures. 70 µL of mineral oil was added to the top of the wells to prevent 
evaporation. Propidium iodide (PI) at 5 µM was also added to the cultures to monitor cell death8. 
The plate was then moved to a BioTek Synergy 4 plate reader and incubated under shaking 
conditions at 37 ºC for 24 hrs. After incubation, cultures were serially diluted in buffer and 
plated for colony forming units (CFUs) on LB agar, and survival in the presence of PYO was 
compared to the no-PYO control. Plates were incubated at room temperature (RT) and CFUs 
were counted after 36-48 hrs. In this study, a stereoscope was always used to count the CFUs. 
Survival levels were calculated for each mutant (i.e. for each replicate, the % survival for 
“+PYO” was calculated based on CFUs for “No PYO”). Then, the survival levels for each 
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mutant were normalized by the survival levels of the ∆phz parent strain (i.e. % survival for 
“+PYO” for each mutant was divided by the average % survival for “+PYO” of the ∆phz strain); 
these “fitness” values were log2 transformed for plotting.  
 
PYO survival with efflux inhibitor  
 Survival assays with efflux inhibition were performed to test the importance of efflux 
systems in P. aeruginosa for tolerance against PYO toxicity. From a ∆phz overnight culture pre-
grown in SMM (20 mM succinate), a new 7 mL culture was started in fresh SMM at an OD500 of 
0.05 and was incubated for around 10 hrs (enough to reach stationary phase). Cells were then 
pelleted, washed and re-suspended in MPB at an OD500 of 1 (10 mL of culture was prepared). 
The culture was then split into four different treatments: (i) no PYO, no PAβN; (ii) 100 µM 
PYO, no PAβN; (iii) no PYO, with PAβN (50 µg/mL) and (iv) 100 µM PYO, with PAβN. Each 
of the treatments were split across 12 wells containing 150 µL of culture + 70 µL of mineral oil 
in a 96-well plate. The plate was incubated at 37 ºC under shaking conditions using a BioTek 
Synergy 4 plate reader. Samples were serially diluted in MPB and plated for CFUs on LB agar 
after 12, 24 and 48 hrs. Survival for treatments containing PYO were calculated based on the 
CFUs counted for the negative control without PYO (Fig. 1C). At each time point, four wells 
were sampled, with each well considered an independent replicate. The experiment was repeated 
twice with similar results. 
 
Antibiotic tolerance experiments using P. aeruginosa 
Tolerance assay for WT, ∆phz and ∆phz + PYO: For most antibiotic tolerance assays 
(except for tolerance using cells harvested during log-phase, see below), the experimental design 
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shown in Fig. S5A was followed. WT and ∆phz cells were grown from a plate into an overnight 
culture in GMM. The overnight cultures were grown in GMM with 20 mM glucose. Next, cells 
were pelleted, washed and re-suspended at an OD500 of 0.05 (four replicates) in GMM (10 mM 
glucose) and incubated for around 20 hrs, reaching stationary phase, in 7 mL cultures (18 x 150 
mm glass tubes). Three treatments were prepared: WT, ∆phz (no PYO) and ∆phz + 100 µM 
PYO. Cultures were then split into a negative control (no antibiotic) or antibiotic treatment (2 
mL of culture per each treatment, using plastic Falcon tubes, VWR® Cat. No. 352059). After 
addition of the antibiotic from concentrated stocks, cultures were incubated for four hours, 
serially diluted in MPB and then plated for CFUs on LB agar. Ciprofloxacin and levofloxacin 
were used at the concentrations mentioned in figure legends. Plates were incubated at RT and 
CFUs were counted after 36-48 hrs. Plates were always checked again after seven days to count 
any late-arising CFUs.  
The same protocol was followed for the experiment testing different concentrations of 
PYO (Fig. 2F) and for the experiment testing how PYO impacts tolerance of different P. 
aeruginosa ciprofloxacin partially-resistant mutants (CipR-21, 25, 33 and 40, Fig. S8E). For the 
experiment testing tolerance after exposure to different phenazines (Fig. S5E), all the phenazines 
were dissolved in a common solvent (DMSO), which was used as the negative control; these 
experiments were performed in a ∆phz* mutant lacking not only the phzA-G1 and phzA-G2 
operons but also all phenazine modification genes, to prevent the transformation of phenazine 1-
carboxylic acid (PCA) into the other phenazines. For experiments performed in synthetic cystic 
fibrosis sputum medium SCFM (Fig. 2C), the same experimental design was followed, with the 
exception that SCFM was used instead of GMM.  
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Tolerance assay for strains with arabinose-inducible constructs: For these experiments 
(Fig. 2G and S7B), the 20 hrs cultures of each strain (∆phz Para:mexGHI-opmD, ∆phz Para:ahpB 
and ∆phz Para:katB) were grown with and without 20 mM arabinose for induction of the 
controlled systems, and then exposed to ciprofloxacin the same way described above. To rule out 
any non-specific interference of the inducer, negative controls with and without 20 mM 
arabinose using the parent ∆phz strain (without the insertions in the attTn7 site) were also done. 
Adding arabinose to the ∆phz strain did not impact tolerance levels (Fig. S7).  
Tolerance assay with PAβN: Experiments using the efflux inhibitor PAβN (Fig. S5F) 
were also performed similarly to the way as described above. The only differences were that 
after the 20 hrs incubation and before the addition of the antibiotic, PAβN was added to the 
cultures at a final concentration of 50 µg/mL. Cultures were incubated for 15 min and then 
ciprofloxacin was added, followed by four-hour incubation. For these experiments, instead of 
plating cells directly on LB, 1 mL of culture of each replicate/treatment was pelleted (12500 rpm 
for 2 min), washed in MPB for removal of CP and PAβN, and only then serially diluted in MPB 
and plated on LB for CFU counting.  
Tolerance assay for cells harvested during log-phase: ∆phz cells were grown in overnight 
cultures in GMM (20 mM glucose). Next, cells were pelleted, washed and re-suspended into two 
new cultures, one with PYO (100 µM) and one without PYO, at an OD500 of 0.05 in GMM (10 
mM glucose, 7 mL cultures). Cultures were grown until OD500 = 0.5 (around 5-6 hrs). Cells were 
then washed and re-suspended in the same medium at an OD500 of 0.5, but without the nitrogen 
source (i.e. no NH4Cl). PYO was re-added after washes to the culture that was pre-grown with 
PYO. The cultures, one with and one without PYO, were then split into different treatments: 
negative control (no antibiotic), ciprofloxacin (0.5 µg/mL), levofloxacin (1 µg/mL), gentamicin 
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(16 µg/mL) and tobramycin (4 µg/mL). Then, they were all transferred to wells in a 96-well plate 
(three to four wells per treatment, with each well being considered an independent replicate). 
Cultures within wells contained 150 µL with an additional 70 µL of mineral oil on top to prevent 
evaporation. The depletion of nitrogen prevented growth in the negative control, which limited 
overestimation of the antibiotic killing effect (because survival rates were calculated relative to 
the negative control). The plates were incubated for four hours at 37 ºC under shaking conditions 
(175 rpm) using a benchtop incubator (VWR® incubator orbital shaker). The 96-well plate was 
kept inside an airtight plastic container with several wet paper towels to maintain high humidity 
attached to the shaker. After incubation, cells were serially diluted and plated on LB agar for 
CFU counting (Fig. S5B). A similar experiment was also performed with the strains containing 
arabinose-inducible constructs (∆phz Para:mexGHI-opmD, ∆phz Para:ahpB and ∆phz Para:katB) 
and the ∆phz background control (Fig. S7A), for which tolerance to ciprofloxacin (0.5 µg/mL) 
was tested. The experiment followed the same protocol described above, with the difference that, 
instead of presence or absence of PYO, strains were incubated in the presence or absence of 20 
mM arabinose.  
 
Time-lapse microscopy experiment and quantification 
Fluorescently tagged strains of WT or ∆phz were grown in GMM and tolerance 
experiments were performed as shown in Fig. S5D using ciprofloxacin (10 µg/mL). After the 
four-hour incubation with the antibiotic, cells were washed and re-suspended in GMM. The two 
different strains were then mixed and placed on an agarose pad containing GMM (no 
ciprofloxacin or PYO was added to the pad). Agarose pads were placed into a PELCO® Clear 
Wall Glass Bottom Dish (Cat. No. 14023-20), and the dish was used for imaging within the 
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microscope incubation chamber. Outgrowth was visualized using a Nikon Ti2E microscope with 
Perfect Focus System 4. Incubation proceeded for 12.5 to 15 hrs at 37 ºC, with imaging every 15 
min in bright field (phase contrast), green and red fluorescence channels (50 ms exposure with 
470 nm LED lamp and a green-FITC filter [ex = 465-495nm, em = 515-555nm] for the GFP; 50 
ms exposure with 555 nm LED lamp and a quad band filter [red ex = 543-566nm, red em = 580-
611nm] for mApple).  
For image analysis, a Fiji macro was used (available upon request). Briefly, fluorescent 
channels (GFP/mApple) of the first and last time points were segmented using the “Auto 
Threshold” function and “Default” setting. The area of the segmented cells was then recorded 
using the “Analyze Particles” function in Fiji74. This allowed for quantification of the total area 
covered by cells within each channel, with each field of view being processed separately. After 
that, for each field of view, the total area covered by WT cells (or ∆phz + 100 µM PYO, 
depending on the experiment) was divided by the area covered by ∆phz cells to obtain the 
relative “growth area ratios”. This was done for first and last time points. Three experiments 
were performed, with different fluorescent protein/strain combinations: (i) 
WT::mApple/∆phz::GFP (n = 13 fields of view, Fig. 2D, E, movie S1); (ii) 
∆phz+PYO::GFP/∆phz::mApple (n = 19, Fig. 2E); and (iii) WT::GFP/∆phz::mApple (n = 16, 
Fig. S5E). GFP/mApple were controlled by the rpsG promoter for all of the strains (Table S4).  
 
RNA extraction and quantitative reverse transcriptase PCR (qRT-PCR) 
Experiment 1 – measurement of PYO-induced gene expression: Six different treatments 
were prepared for this qRT-PCR experiment: (i) WT PA14, (ii) ∆phz, (iii) ∆phz + 1 µM PYO, 
(iv) ∆phz + 10 µM PYO, (v) ∆phz + 100 µM PYO and (vi) ∆phz + 200 µM PYO. Cultures of 
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WT or ∆phz were grown overnight in GMM (20 mM glucose), then cells were washed and 
resuspended at an OD500 of 0.05 (three replicates) in fresh GMM (5 mL in culture tubes). 
Different concentrations of PYO were added to ∆phz cultures as mentioned and all cultures were 
incubated for around 8.5 hrs (until early stationary phase). This was enough time for WT to make 
PYO (around 50-70 µM, measured by absorbance at OD69175). After incubation, cells were 
pelleted, immediately frozen using liquid nitrogen and stored at -80 ºC. 
Experiment 2 – measuring arabinose induction of mexGHI-opmD, ahpB and katB: Eight 
different treatments were prepared for this qRT-PCR experiment, in which each of the four 
tested strains (∆phz, ∆phz Para:mexGHI-opmD, ∆phz Para:ahpB and ∆phz Para:katB) were 
incubated with and without 20 mM arabinose for artificial induction of the constructs. Cultures 
of the four strains were grown overnight in GMM (20 mM glucose), then cells were washed and 
resuspended at an OD500 of 0.05 (three replicates) in the same medium (5 mL in culture tubes), 
with and without 20 mM arabinose (for conditions without arabinose, the respective amount of 
water was added). Cultures were incubated for around 8.5 hrs, then pelleted, immediately frozen 
using liquid nitrogen and stored at – 80 ºC. 
For RNA extraction, previously published protocols were followed8,63. Briefly, samples 
were thawed in ice for 10 min and re-suspended in 215 µL of TE buffer (30 mM Tris.Cl, 1 mM 
EDTA, pH 8.0) containing 15 mg/mL of lysozyme + 15 µL of proteinase K solution (20 mg/mL, 
Qiagen), and then incubated for 8–10 min. For Lysis steps and RNA extractions it was used the 
RNeasy kit (Qiagen). Samples were then treated with TURBO DNA-free kit (Invitrogen) for 
removal of any contaminant gDNA. Next, cDNA was synthesized using iScript cDNA Synthesis 
kit (Bio-Rad) (1 µg of total RNA was used). For all these steps using kits, manufacturer’s 
instructions were followed. qRT-PCR reactions were performed using iTaq Universal SYBR 
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Green Supermix (Bio-Rad) in 20 µL reactions using a 7500 Fast Real-Time PCR System 
machine (Applied Biosystems) following published protocols8. Standard curves for each primer 
pair were prepared using P. aeruginosa gDNA and were used for calculation of cDNA for each 
gene studied. The house-keeping gene oprI was used as a control gene for normalizations63. 
Data showing total oprI-normalized cDNA levels (i.e. cDNA measured for a certain gene 
in a certain sample, divided by the respective cDNA measured for oprI in the same sample) and 
the log2-fold change in expression are shown in Figs. 2B and Figs. S2, S3 and S4. cDNA values 
for replicates within each efflux gene/treatment (shown in Fig. S3) were averaged and used with 
the geom_tile() function in R71,72 for generation of the heatmap shown in Fig. 2B. 
 
Stenotrophomonas and Burkholderia growth curves and antibiotic tolerance assays 
 Stenotrophomonas maltophilia ATCC 13637, Burkholderia cepacia ATCC 25416, B. 
cenocepacia AU42085, B. multivorans AU42096 (B. multivorans 1), and B. gladioli AU42104 
were used in the growth experiments shown in Fig. S10A (for strain details, see Table S4). Each 
strain was grown overnight in GMM (20 mM glucose, 5 mL culture tubes) supplemented with 1x 
MEM amino acids (AA) (Sigma, Cat. No. M5550). Cells were pelleted, washed and re-
suspended in new cultures at an OD500 of 0.05 in the same medium. Cultures were then split, 
different concentrations of PYO were added (0, 10, 50 or 100 µM for S. maltophilia; 0, 10 or 100 
µM for all others), and moved to a 96-well plate (4 to 6 wells per treatment, with each well being 
considered an independent replicate). Cultures within wells contained 150 µL with an additional 
70 µL of mineral oil on top to prevent evaporation. The plates were incubated at 37 ºC under 
shaking conditions using a BioTek Synergy 4 plate reader with OD500 measurements every 15 
min for 24 hrs to measure growth. Assays for tolerance to ciprofloxacin with or without 
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exogenous PYO were performed for S. maltophilia (sensitive to PYO) and for four Burkholderia 
strains (all resistant to PYO): B. cepacia, B. cenocepacia, B. multivorans 1 and B. multivorans 
AU18358 (B. multivorans 4). The experiments followed exactly what was done for P. 
aeruginosa (Fig. S5A), except that cultures were grown in GMM + AA, and are shown in Figs. 
4A, 4B and S10C. 
 
Co-culture antibiotic tolerance experiments 
 To test how PYO produced by P. aeruginosa impacts tolerance to ciprofloxacin in other 
species, co-culture experiments were performed using membrane-separated 12-well tissue plate 
cultures containing 0.1 µm pore PET membranes (VWR® Cat. No. 10769-226). Briefly, 
overnight cultures of the P. aeruginosa strain (WT/∆phz PA14 or PA 76-11) and the respective 
other species tested (S. maltophilia, B. cepacia, B. cenocepacia or B. multivorans 1) were 
prepared in GMM (20 mM glucose) + AA. Cells were pelleted, washed and re-suspended to 
different ODs as follows: (i) for any P. aeruginosa-Burkholderia assay, P. aeruginosa starting 
OD500 = 0.05 and Burkholderia starting OD500 = 0.025; (ii) for the P. aeruginosa-S. maltophilia 
assay, P. aeruginosa starting OD500 = 0.01 and S. maltophilia starting OD500 = 0.1. P. aeruginosa 
was cultured in the bottom part of the well (600 µL), while the other species was cultured in the 
upper part of the well (100 µL), as shown in Fig. S10B. B. cepacia and S. maltophilia were 
cultured either with WT or ∆phz P. aeruginosa PA14 (with and without 100 µM PYO 
exogenously added). B. cenocepacia and B. multivorans 1 were cultured either with PA 76-11 (a 
P. aeruginosa strain isolated from CF sputum that produced 50-100 µM PYO in these assays) or 
alone in the presence or absence of 100 µM PYO. For cases where Burkholderia was grown 
alone, the strain tested was grown in both the bottom and top parts of the membrane-separated 
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wells. In all experiments, co-cultures were grown for around 20 hrs at 37 ºC under shaking 
conditions (175 rpm) using a benchtop incubator, followed by addition of ciprofloxacin 
(concentrations were either 1 or 10 µg/mL, as specified in the figure legends) and incubation for 
four hours. The membrane-separated plates were kept inside an airtight plastic container with 
several wet paper towels to maintain high humidity attached to the shaker. For every co-culture 
combination in the membrane-separated plate, three wells were used as a negative control (no 
antibiotic) and three wells were used for ciprofloxacin treatment; each well was considered an 
independent replicate. After incubation with ciprofloxacin, cells were serially diluted in MPB 
and plated for CFUs on LB. In most cases, only Burkholderia cells were plated (Fig. 4C and Fig 
S10E). However, a co-culture experiment was also performed in SCFM (P. aeruginosa PA14 
WT/∆phz with B. multivorans 1) and in this case, both P. aeruginosa and B. multivorans 1 were 
plated for CFUs (Fig. S10F). This experiment in SCFM followed the same overall experimental 
design used before, except for using SCFM instead of GMM in all steps.  
 
Determination of minimum inhibitory concentrations  
 MICs were determined using an agar dilution assay, in order to guide the choice of 
antibiotic concentrations for selecting de novo antibiotic-resistant mutants. Overnight cultures 
were grown for each strain in GMM (with 10 mM glucose) or GMM (10 mM glucose) + AA, 
respectively, then diluted to an OD500 of 0.5, from which 3 µL was spotted onto MH agar 
containing a 2-fold dilution series of the antibiotic. After the spots dried, the antibiotic plates 
were incubated upside-down for 48 hrs at 37°C before assessing the spots for growth. We 
considered the MIC to be the first concentration at which there was neither a lawn of background 
growth, nor dozens of overlapping colonies visible without magnification. We generally used 2x 
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the MIC as the selection condition for fluctuation tests; for P. aeruginosa, this corresponded to 
the EUCAST resistance breakpoints for ciprofloxacin and levofloxacin, while our chosen 
concentrations of gentamicin and tobramycin were two-fold higher than the EUCAST 
breakpoints25. EUCAST breakpoints are not available for Stenotrophomonas spp. or the 
Burkholderia cepacia complex. The appropriateness of the selection condition for was 
additionally verified by performing a fluctuation test, as described below, and choosing the 
antibiotic concentration that reliably yielded a countable number of colonies (zero to several 
dozen, with at least several non-zero counts per 44 parallel cultures) in each well.    
 
Fluctuation tests, calculation of mutation rates, and model fitting 
 For all tested strains and conditions, fluctuation tests were performed by inoculating 200 
µL cultures in parallel in a flat-bottomed 96-well plate. All reported fluctuation test data for P. 
aeruginosa are from experiments using the ∆phz strain. We also performed fluctuation tests 
using the P. aeruginosa PA14 WT strain, and performed phenotypic and genotypic 
characterization of partially-resistant mutants detected in those experiments (see below); 
however, the effect of PYO on apparent mutation rates in WT was difficult to interpret due to 
inconsistent PYO production in the 96-well plates. For cultures that were grown with PYO (or 
arabinose in the case of strains with arabinose-inducible constructs), the PYO (or 20 mM 
arabinose) was added to the medium before inoculation. The cultures were inoculated with a 10-6 
dilution of a single overnight culture (representing a biological replicate) that had first been 
diluted to a standard OD500 of 1.0, corresponding to an initial cell density of approximately 2000-
2500 CFUs/mL (400-500 cells/culture). Each treatment condition consisted of 44 such parallel 
cultures. The 96-well plates were placed inside an airtight plastic container with several wet 
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paper towels to maintain high humidity, then incubated at 37°C with shaking at 250 rpm. For 
plating during log-phase, the cultures were incubated until reaching approximately half-maximal 
density (OD500 of 0.4-0.7 for P. aeruginosa in GMM with 10 mM glucose, or 0.9-1.2 for P. 
aeruginosa in SCFM or B. multivorans in GMM + AA). For plating during stationary phase, the 
cultures were incubated for 24 hrs. The cultures were then plated by spotting 40-50 µL per 
culture into single wells of 24-well plates (for any given experiment, the same volume was 
spotted for all parallel cultures); each well contained 1 mL of MH agar or SFCM agar plus an 
antibiotic, with or without 100 µM PYO (or 20 mM arabinose for strains with arabinose-
inducible constructs). In the case of B. multivorans cultures that were spotted onto antibiotic 
plates containing 100 µM PYO, the cultures were first diluted 1:10 (if not pre-treated with 100 
µM PYO) or 1:100 (if pre-treated with 100 µM PYO). At the same time as plating onto the 
antibiotic plates, six representative cultures from each treatment were serially diluted and plated 
on LB agar plates to assess total CFUs. The antibiotic plates were incubated upside down, in 
stacks of no more than eight, at 37°C for 16-24 hrs for P. aeruginosa (except for gentamicin 
plates, which were incubated for 40-48 hrs) or 40-48 hrs for B. multivorans. Subsequently, 
colonies were counted under a stereoscope at the highest magnification for which the field of 
view still encompassed an entire well; occasionally, a well contained too many colonies to count 
(a so-called “jackpot” culture76), in which case that culture was discarded from further analysis. 
The LB agar plates for total CFU counts were incubated for 30-36 hrs at RT before counting 
colonies at the same magnification.   
 Mutation rates reported in the figures were calculated using the function 
newton.LD.plating from the R package rsalvador77 to estimate m, the expected number of 
mutations per culture. This is a maximum likelihood-based method for inferring mutation rates 
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from fluctuation test colony counts, based on the classic Luria-Delbrück (LD) distribution with a 
correction to account for the effects of partial plating (i.e. plating a portion of each culture rather 
than the total volume)77. We chose this method because it has been shown to be the most 
accurate estimator of m when partial plating is involved77,78. To get µapp (apparent mutation rate 
per generation) from m, we divided m by the total number of cells per parallel culture77, as 
estimated from the mean number of CFUs counted for the six representative cultures.  
 To compare the fits of different formulations of the LD distribution to our data, we 
generated theoretical cumulative distributions using the parameter values estimated for our data. 
Specifically, for the Hamon and Ycart version of the LD model32, we estimated m and w (relative 
fitness of mutants compared to the parent strain in the non-selective pre-plating liquid growth 
medium) using the function GF.est from the R script available at 
http://ljk.imag.fr/membres/Bernard.Ycart/LD/ (version 1.0; note that in the script, m is called 
alpha and 1/w is called rho); then, we used the function pLD from the same script to generate the 
theoretical distribution. For the mixed LD-Poisson and basic LD models, we wrote and used an 
R translation of the MATLAB code written by Lang et al.33; the original code is available at 
https://github.com/AWMurrayLab/FluctuationTest_GregLang. The basic LD model used by 
Lang et al. is equivalent to that available in the rsalvador package (using the function 
newton.LD), except without the correction for partial plating; the latter is only important when 
using the estimate of m to infer the mutation rate, not when comparing the fits of different 
models to the empirical cumulative distribution of the raw colony counts.  
Plots of the empirical cumulative distributions of our data against the theoretical models 
showed that the Hamon and Ycart model was a visually good fit in all cases (see Fig. S9 and S11 
for examples). To further assess goodness-of-fit of the Hamon and Ycart model, we performed 
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Pearson’s chi-square test in R after binning the data and theoretical distribution such that the 
expected number of cultures in each bin of mutant counts was at least five79. To compare the 
goodness-of-fit of the Hamon and Ycart model to the basic LD model, we calculated the negative 
log-likelihood for each model and performed the likelihood ratio test. To compare the Hamon 
and Ycart model to the mixed LD-Poisson model, we simply compared the negative log-
likelihoods (smaller values indicate a better fit); the likelihood ratio test was not applicable as 
these two models contain the same number of parameters. Note that although the Hamon and 
Ycart (or in some cases, LD-Poisson) models were often better fits than the basic LD model, we 
still used the basic LD model for statistical comparison of mutation rates between conditions, 
because an accurate method to account for partial plating has not yet been developed for the 
cases of post-plating mutations or differential fitness between mutants and parent strains77. 
Nevertheless, similar patterns in mutation rates were observed when using an older method of 
accounting for partial plating to derive µapp from the Hamon and Ycart model80, indicating that 
the effects of PYO were robust to different mathematical methods of inferring mutation rates 
from fluctuation test data (Table S2). 
 
Characterization of antibiotic resistance phenotypes 
 We defined putative ciprofloxacin-resistant mutants as “enriched” by PYO in the 
fluctuation tests if colonies with a given morphology were at least 2x more numerous on the 
PYO-containing ciprofloxacin plate than the respective non-PYO-containing ciprofloxacin plate 
derived from the same 200 µL culture. These putative mutants could be either from the PYO pre-
treated or non-PYO pre-treated branches of the fluctuation test. Putative mutants that were 
seemingly enriched by PYO were restreaked for purity on PYO-containing agar plates at the 
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same ciprofloxacin concentration on which they were selected in the fluctuation test (0.5 µg/mL 
for PA, 8 µg/mL for B. multivorans). Putative mutants that were not enriched by PYO were 
restreaked on ciprofloxacin agar plates without PYO. Frozen stocks of each restreaked, visually 
pure isolate were prepared by inoculating cultures with single colonies in 5 mL of liquid LB, 
incubating to stationary phase, mixing 1:1 with 50% glycerol, and storing at -80°C.  
   The levels of ciprofloxacin resistance of selected isolates, as well as the parent strains, 
were assessed using a CFU recovery assay as follows. For each isolate, four 5 mL cultures in 
GMM (for P. aeruginosa) or GMM + AA (for B. multivorans) were inoculated directly from the 
frozen stock, to minimize the number of generations in which secondary mutations could be 
acquired. The cultures were grown to stationary phase overnight, then subcultured to an OD500 of 
0.05 in 5 mL of fresh GMM (for P. aeruginosa) or GMM + AA (for B. multivorans), with or 
without 100 µM PYO. The new cultures were grown to mid log-phase, then serially diluted in 
GMM or GMM + AA (+/- 100 µM PYO as appropriate) and plated for CFUs (10 µL per dilution 
step) on 1) plain MH agar, 2) MH agar + ciprofloxacin, and 3) MH agar + ciprofloxacin + 100 
µM PYO. The lowest plated dilution was 10-1, making the limit of detection approximately 1000 
CFUs/mL.  
 
Identification of mutations by whole-genome sequencing 
 Genomic DNA was isolated from selected putative mutants and the parent strains using 
the DNeasy Blood & Tissue kit (Qiagen). Library preparation and 2x150 bp paired-end Illumina 
sequencing was performed by the Microbial Genome Sequencing Center (Pittsburgh, PA), with a 
minimum of 300 Mb sequencing output per sample (~50x coverage). Forward and reverse 
sequencing reads were concatenated into a single file for each isolate and quality control was 
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performed using Trimmomatic (version 0.39)81 with the following settings: LEADING:27 
TRAILING:27 SLIDINGWINDOW:4:27 MINLEN:35. Mutations were then identified using 
breseq (version 0.34.1)82. The annotated reference genome for P. aeruginosa UCBPP-PA14 was 
obtained from BioProject accession number PRJNA38507. For B. multivorans AU42096, no 
reference genome was available from NCBI. Therefore, a genome scaffold was assembled from 
the paired-end sequencing data for the parent strain using SPAdes (version 3.14.0) with default 
parameters83. This scaffold was then used as the reference for breseq. Differences between the 
parent strain and isolates were identified using the gdtools utility that comes with breseq to 
compare the respective breseq outputs. All sequenced P. aeruginosa mutants were derived from 
the ∆phz strain except for CipR-33 and CipR-40, which were derived from the WT strain. In the 
case of B. multivorans, several dozen putative mutations were identified that were common to all 
three sequenced putative mutants. We assumed that these represented assembly errors in the 
parent strain genome scaffold, but even if they were genuine mutations, these would not account 
for the phenotypic differences between the isolates; therefore, Table S5 reports only mutations 
that were unique to each isolate. The genomic loci containing each putative mutation for the B. 
multivorans isolates were identified by retrieving the surrounding 200 bp from the parent 
genome scaffold and using the nucleotide BLAST tool on the MicroScope platform84 to find the 
closest match in the B. multivorans ATCC 17616 genome.   
 
Statistical analyses 
All statistical analyses were performed using R72. Welch’s unpaired t-tests or one-way 
ANOVA with post hoc Tukey’s HSD test for multiple comparisons were used for tolerance assay 
data. Welch’s paired t-tests with Benjamini-Hochberg corrections for controlling false discovery 
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rates were used for comparisons of apparent mutation rates across different conditions. Welch’s 
unpaired t-tests with Benjamini-Hochberg corrections for controlling false discovery rates were 
used for comparisons of CFU recovery on ciprofloxacin plates under different PYO treatments. 
For all antibiotic tolerance assays measured by CFUs, survival data were log10-transformed 
before statistical analyses. 
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